Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Renin-Angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry.

Núñez-Gil, IJ, Olier, I, Feltes, G, Viana-Llamas, MC, Maroun-Eid, C, Romero, R, Fernández-Rozas, I, Uribarri, A, Becerra-Muñoz, VM, Alfonso-Rodriguez, E, García-Aguado, M, Elola, J, Castro-Mejía, A, Pepe, M, Garcia-Prieto, JF, Gonzalez, A, Ugo, F, Cerrato, E, Bondia, E, Raposeiras, S , Mendez, JLJ, Espejo, C, Masjuan, ÁL, Marin, F, López-Pais, J, Abumayyaleh, M, Corbi-Pascual, M, Liebetrau, C, Ramakrisna, H, Estrada, V, Macaya, C and HOPE COVID-19 investigators (Cols appendix), (2021) Renin-Angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry. American Heart Journal, 237. pp. 104-115. ISSN 0002-8703

[img] Text
Renin-Angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcome.pdf - Accepted Version
Restricted to Repository staff only until 15 April 2022.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (927kB)

Abstract

BACKGROUND: The use of Renin-Angiotensin system inhibitors (RASi) in patients with coronavirus disease 2019 (COVID-19) has been questioned because both share a target receptor site. METHODS: HOPE-COVID-19 (NCT04334291) is an international investigator-initiated registry. Patients are eligible when discharged after an in-hospital stay with COVID-19, dead or alive. Here, we analyze the impact of previous and continued in-hospital treatment with RASi in all-cause mortality and the development of in-stay complications. RESULTS: We included 6503 patients, over 18 years, from Spain and Italy with data on their RASi status. Of those, 36.8% were receiving any RASi before admission. RASi patients were older, more frequently male, with more comorbidities and frailer. Their probability of death and ICU admission was higher. However, after adjustment, these differences disappeared. Regarding RASi in-hospital use, those who continued the treatment were younger, with balanced comorbidities but with less severe COVID19. Raw mortality and secondary events were less frequent in RASi. After adjustment, patients receiving RASi still presented significantly better outcomes, with less mortality, ICU admissions, respiratory insufficiency, need for mechanical ventilation or prone, sepsis, SIRS and renal failure (p<0.05 for all). However, we did not find differences regarding the hospital use of RASi and the development of heart failure. CONCLUSION: RASi historic use, at admission, is not related to an adjusted worse prognosis in hospitalized COVID-19 patients, although it points out a high-risk population. In this setting, the in-hospital prescription of RASi is associated with improved survival and fewer short-term complications.

Item Type: Article
Uncontrolled Keywords: 1102 Cardiorespiratory Medicine and Haematology, 1117 Public Health and Health Services
Subjects: Q Science > QA Mathematics > QA75 Electronic computers. Computer science
R Medicine > R Medicine (General)
Divisions: Computer Science & Mathematics
Publisher: Elsevier
Related URLs:
Date Deposited: 30 Apr 2021 12:15
Last Modified: 04 Sep 2021 05:31
DOI or Identification number: 10.1016/j.ahj.2021.04.001
URI: https://researchonline.ljmu.ac.uk/id/eprint/14894

Actions (login required)

View Item View Item